Navigation Links
Lotus Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results
Date:8/14/2009

p> This press release contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intent," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may," or words or expressions of similar meaning. Such statements are not guarantees of future performance and could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including, but not limited to, changes from anticipated levels of sales, future national or regional economic and competitive and regulatory conditions, changes in relationships with customers, access to capital, increased costs, difficulties in developing and marketing new products, marketing existing products, customer acceptance of existing and new products, the time to get new drugs approved by the SFDA and other factors. Additional information regarding risks can be found in the Company's Annual Report on Form 10K and its older filings with the SEC. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this press release.



                 LOTUS PHARMACEUTICALS, INC. AND SUBSIDIARIES
                           CONSOLIDATED BALANCE SHEETS

                                             June 30, 2009  December 31,2008
                                                (Unaudited)
    ASSETS
    CURRENT ASSETS:
    Cash                                        $1,830,366     
'/>"/>
SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Lotus Pharmaceuticals, Inc. Announces Patent Pending Gliclazide-Controlled Release Tablets
2. Lotus Scarless Hair Transplantation (International) Medical Chain Institute Opens New Center on Beijings Prestigious ChangAn Avenue
3. Lotus Pharmaceuticals Announces Second Quarter 2008 Results
4. NovaBay Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results
5. Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
6. Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday, August 14, 2009 at 10:30 a.m. EDT
7. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
8. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
10. Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States
11. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Surrey have discovered how the receptors responsible for contractions ... The new study, published today in The FASEB ... turn regulates the cycle of all cells in the ... local biological clock and its control are weakened in ... bladder physiology and ageing. , While currently ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Ophthalmic ... the interesting and challenging endeavors as the anatomy, ... impervious properties to the foreign substances. Ocular drug ... of self medication and minimal use of needles; ... weight drugs and provides specific targeting within the ...
(Date:8/22/2014)... August 22, 2014 The AMA is ... its members in Alaska that Alaska Governor Sean Parnell ... 15, further defining public use of Unmanned Aircraft Systems ... Force. House Bill 255states that it is, “An Act ... captured by an unmanned aircraft system.” It defines State ...
(Date:8/21/2014)... 2014  BioSpecifics Technologies Corp. (NASDAQ: ... class collagenase-based products marketed as XIAFLEX ® ... and XIAPEX ® in the EU, today ... double-blind Phase 2a study of CCH for the ... The results showed that all three doses of ...
Breaking Biology Technology:Treatment for overactive bladder and irritable bowel syndrome advanced through pioneering research 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4State of Alaska Signs Unmanned Aircraft Systems Bill 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5
... DIEGO, Sept. 9 Orexigen((R) )Therapeutics, Inc. (Nasdaq: OREX ), a ... will be speaking at two upcoming investor conferences. The details are as ... Stanley Global Healthcare Unplugged Conference, Date: September 15, 2009, ... Grand Hyatt Hotel, New York, Speaker: Michael Narachi, President ...
... TAI,AN, China, Sept. ... Bulletin Board: CBPO) ("China Biologic," or the ... in the People,s,Republic of China ("PRC"), operating ... Products Co. Ltd. ("Taibang") and,Chongqing Dalin Biologic ...
... , , THE WOODLANDS, ... LXRX ), a biopharmaceutical company focused on discovering and developing ... Sands, M.D., Ph.D. , Lexicon,s president and chief executive officer, will ... Hyatt hotel in New York, New York on Tuesday, September 15, 2009 ...
Cached Biology Technology:China Biologic Products Appoints Director of Research and Development 2China Biologic Products Appoints Director of Research and Development 3Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2
(Date:8/22/2014)... and clinical research and technological advances, the fight ... spanning multiple fronts. , Work happening in a ... new and more selective therapies for cancer. Researchers ... enzyme overexpressed in certain cancersand they have tested ... Chemistry professor Christopher Cairo and his team synthesized ...
(Date:8/22/2014)... of captive black rhino reproduction in Europe highlights ... breeding programmes. , Researchers from Chester Zoo, The ... carried out a six-year study which encompassed 90% ... Katie Edwards led the research as part of ... says: "Although some black rhinoceros breed well in ...
(Date:8/22/2014)... is a multifunctional enzyme that localizes ... neuroprotective and cholesterol-synthesizing activities. DHCR24 overexpression ... amyloid β deposition. Dr. Xiuli Lu ... China constructed two recombinant adenoviruses (Ad-rSYN1-DHCR24-myc ... specifically in neuronal cells. They also ...
Breaking Biology News(10 mins):New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3Hormone analysis helps identify horny rhinos 2
... increases resulting from climate change in the Southwest will likely ... in 60 to 90 years, according to a new study ... research team used models of future climate, an analysis of ... and the fossil record to project the future distribution of ...
... on Osteoporosis & Osteoarthritis by investigators from the UK ... fractures in five major European countries totals 31 billion ... of the economic burden is shown to be related ... the fracture, while pharmacological prevention and treatment management constitutes ...
... Researchers with the Los Angeles County Department of Public ... pathogen, carbapenem-resistant Klebsiella pneumoniae (CRKP) among the patient population ... care hospitals across the county. These findings are ... to East Coast facilities and communities. These findings will ...
Cached Biology News:Uncertain future for Joshua trees projected with climate change 2Drug-resistant pathogen found in large numbers in LA County 2
Mouse Amphiregulin MAb (Clone 206220)...
Anti-Digoxigenin-AP, Fab fragments; from sheep...
The antibody recognizes the peptide sequence ESESQGPK (aa 441-448) of human class III beta-tubulin specific for neurones....
Unique enzyme blend containing Taq and Pwo DNA Polymerase and another thermostable enzyme. The Expand 20 kbPLUS PCR System also includes an optimized reaction buffer, MgCl2 solution, and a human cont...
Biology Products: